Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2023;34(4):418-26
Article Links
Disease Profile and Achievement of Therapeutic Goals in a Modern, Nationwide Cohort of 923 Patients with Psoriatic Arthritis
George E. Fragoulis1, Charalampos Papagoras2, Sousana Gazi3, Evangelia Mole3, Michael Krikelis3, Paraskevi V. Voulgari4, Evripidis Kaltsonoudis4, Nikolaos Koletsos4, Pelagia Katsimpri5, Dimitrios Boumpas5, Dimitrios Katsifis5, Nikolaos Kougkas6, Theodoros Dimitroulas6, Petros P. Sfikakis1, Maria G. Tektonidou1, Chrysoula Gialouri1, Dimitrios P. Bogdanos7, Theodora Simopoulou7, Christos Koutsianas8, Eugenia Mavrea8, Gkikas Katsifis9, Konstantinos Kottas9, Maria Konsta10, Matthoula Tziafalia10, Evangelia Kataxaki11, Eleni Kalavri12, Kalliopi Klavdianou12, Eleftheria P. Grika13, Charalampos Sfontouris13, Dimitrios Daoussis14, George Iliopoulos14, Ilias Bournazos15, Dimitrios Karokis15, Konstantinos Georganas15, Dimos Patrikos15, Dimitrios Vassilopoulos8
Authors Information
  1. Joint Academic Rheumatology Program, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece
  2. First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
  3. Department of Rheumatology, KAT Hospital, Athens, Greece
  4. Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece
  5. Joint Academic Rheumatology Program, 4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
  6. 4th Department of Medicine, Aristotle University, Thessaloniki, Greece
  7. Department of Rheumatology and Clinical Immunology, University of Thessaly, Larissa, Greece
  8. Joint Academic Rheumatology Program, Clinical Immunology, Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens Medical School, General Hospital of Athens “Hippokration”, Athens, Greece
  9. Rheumatology Clinic, Naval Hospital of Athens, Athens, Greece
  10. Rheumatology Unit, Sismanoglio Hospital, Athens, Greece
  11. Rheumatology Department, General Hospital Elefsinas Thriaseio, Athens, Greece
  12. Department of Rheumatology, "Asklepieion" General Hospital, Athens, Greece
  13. Department of Rheumatology, Evaggelismos Athens General Hospital, Athens, Greece
  14. Department of Rheumatology, Patras University Hospital, University of Patras Medical School, Patras, Greece
  15. Private practice, Athens, Greece
Keywords: psoriatic arthritis, comorbidities, bDMARDs, minimal disease activity, registry
References
  1. Feld J, Chandran V, Haroon N, Inman R, Gladman D. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol 2018;14(6):363-71.
  2. Fragoulis GE, Pappa M, Evangelatos G, Iliopoulos A, Sfikakis PP, Tektonidou MG. Axial psoriatic arthritis and ankylosing spondylitis: same or different? A real-world study with emphasis on comorbidities. Clin Exp Rheumatol 2022;40(7):1267-72.
  3. Fragoulis GE, Evangelatos G, Tentolouris N, Fragkiadaki K, Panopoulos S, Konstantonis G, et al. Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus. Ther Adv Musculoskelet Dis 2020;12:1759720X20976975.
  4. Gialouri CG, Evangelatos G, Fragoulis GE. Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFalpha, IL-17, IL-23 or JAK Inhibitors? Mediterr J Rheumatol 2022;33(Suppl 1):150-61.
  5. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010;34(3):J314-21.
  6. Baraliakos X, Ostergaard M, Lambert RG, Eshed I, Machado PM, Pedersen SJ, et al. MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group. Ann Rheum Dis 2022 May 24:annrheumdis-2021-222081.
  7. Lambert RG, Bakker PA, van der Heijde D, Weber U, Rudwaleit M, Hermann KG, et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Ann Rheum Dis 2016;75(11):1958-63.
  8. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69(1):48-53.
  9. Ayan G, Aydin SZ, Kimyon G, Ozisler C, Tinazzi I, Dogru A, et al. PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis. Rheumatology (Oxford) 2021;60(4):1755-62.
  10. Gladman DD, Chandran V. Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatology (Oxford) 2011;50(1):25-31.
  11. Solmaz D, Bakirci S, Kimyon G, Gunal EK, Dogru A, Bayindir O, et al. Impact of Having Family History of Psoriasis or Psoriatic Arthritis on Psoriatic Disease. Arthritis Care Res (Hoboken) 2020;72(1):63-8.
  12. Cafaro G, McInnes IB. Psoriatic arthritis: tissue-directed inflammation? Clin Rheumatol 2018;37(4):859-68.
  13. Kalyoncu U, Bayindir O, Ferhat Oksuz M, Dogru A, Kimyon G, Tarhan EF, et al. The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients. Rheumatology (Oxford) 2017;56(2):279-86.
  14. Mease PJ, O'Brien J, Middaugh N, Kricorian G, Stryker S, Collier DH, et al. Real-World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR Open Rheumatol 2023;5(8):388-98.
  15. Poddubnyy D, Baraliakos X, Van den Bosch F, Braun J, Coates LC, Chandran V, et al. Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Ther Adv Musculoskelet Dis 2021;13:1759720X211057975.
  16. Kasiem FR, Kok MR, Luime JJ, Tchetverikov I, Wervers K, Korswagen LA, et al. The burden of psoriasis in patients with early psoriatic arthritis. Rheumatology (Oxford) 2022;61(4):1570-8.
  17. De Vicente Delmas A, Sanchez-Bilbao L, Calvo-Rio V, Martinez-Lopez D, Herrero-Morant A, Galindez-Agirregoikoa E, et al. Uveitis in psoriatic arthritis: study of 406 patients in a single university center and literature review. RMD Open 2023;9(1).
  18. Kougkas N, Magiouf K, Gialouri CG, Evangelatos G, Pappa M, Dimouli A, et al. Higher frequency but similar recurrence rate of uveitis episodes in axial spondylarthritis compared to psoriatic arthritis. A multicentre retrospective study. Rheumatol Int 2023;43(11):2081-8.
  19. Ishchenko A, Pazmino S, Neerinckx B, Lories R, de Vlam K. Comorbidities in early psoriatic arthritis: data from METAPSA cohort study. Arthritis Care Res (Hoboken) 2023.
  20. Panagiotopoulos A, Fragoulis GE. Comorbidities in Psoriatic Arthritis: A Narrative Review. Clin Ther 2023;45(2):177-89.
  21. Scriffignano S, Lories R, Nzeusseu Toukap A, Lubrano E, Ciccia F, Steinfeld S, et al. Cardiovascular comorbidities in psoriatic arthritis: epidemiology and risk factors in two different European populations. Clin Exp Rheumatol 2023;41(9):1815-22.
  22. Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013;72(2):211-6.
  23. Thomas K, Lazarini A, Kaltsonoudis E, Drosos A, Papalopoulos I, Sidiropoulos P, et al. Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. Mediterr J Rheumatol 2018;29(1):27-37.
  24. Urruticoechea-Arana A, Castaneda S, Oton T, Benavent D, Loza E, Martin-Martinez MA, et al. Prevalence of Metabolic Syndrome in Psoriatic Arthritis: Systematic Literature Review and Results From the CARMA Cohort. J Clin Rheumatol 2022;28(2):e388-e96.
  25. Tripolino C, Ciaffi J, Ruscitti P, Giacomelli R, Meliconi R, Ursini F. Hyperuricemia in Psoriatic Arthritis: Epidemiology, Pathophysiology, and Clinical Implications. Front Med (Lausanne) 2021;8:737573.
  26. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Gomez-Acebo I, Miranda-Filloy JA, Paz-Carreira J, et al. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2009;39(3):157-62.
  27. Lai TL, Yim CW, Wong PY, Leung MC, Ng WL. Hyperuricemia in Asian psoriatic arthritis patients. Int J Rheum Dis 2018;21(4):843-9.
  28. Colaco K, Lee KA, Akhtari S, Winer R, Chandran V, Harvey P, et al. Derivation and Internal Validation of a Disease-specific Cardiovascular Risk Prediction Model for Patients with Psoriatic Arthritis and Psoriasis. Arthritis Rheumatol 2023 Sep 11. doi: 10.1002/art.42694. Online ahead of print.
  29. Zhao SS, Miller N, Harrison N, Duffield SJ, Dey M, Goodson NJ. Systematic review of mental health comorbidities in psoriatic arthritis. Clin Rheumatol 2020;39(1):217-25.
  30. Gialouri CG, Evangelatos G, Zhao SS, Kouna K, Karamanakos A, Iliopoulos A, et al. Depression and anxiety in a real-world psoriatic arthritis longitudinal study: should we focus more on patients' perception? Clin Exp Rheumatol 2023;41(1):159-65.
  31. Michelsen B, Kristianslund EK, Sexton J, Hammer HB, Fagerli KM, Lie E, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis 2017;76(11):1906-10.
  32. Wong A, Ye JY, Cook RJ, Gladman DD, Chandran V. Depression and Anxiety Reduce the Probability of Achieving a State of Sustained Minimal Disease Activity in Patients With Psoriatic Arthritis. Arthritis Care Res (Hoboken) 2022;74(9):1430-4.
  33. Fragoulis GE, Grigoropoulos I, Mavrea E, Arida A, Bournia VK, Evangelatos G, et al. Increased influenza vaccination rates in patients with autoimmune rheumatic diseases during the Covid-19 pandemic: a cross-sectional study. Rheumatol Int 2021;41(5):895-902.
  34. Lindstrom U, Di Giuseppe D, Delcoigne B, Glintborg B, Moller B, Ciurea A, et al. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Ann Rheum Dis 2021;80(11):1410-8.
  35. Aureal M, Seauve M, Laplane S, Lega JC, Cabrera N, Coury F. Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies. RMD Open 2023;9(3).
  36. McInnes IB, Sawyer LM, Markus K, LeReun C, Sabry-Grant C, Helliwell PS. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open 2022;8(1).
  37. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016;75(5):811-8.
  38. Zardin-Moraes M, da Silva A, Saldanha C, Kohem CL, Coates LC, Henrique LR, et al. Prevalence of Psoriatic Arthritis Patients Achieving Minimal Disease Activity in Real-world Studies and Randomized Clinical Trials: Systematic Review with Metaanalysis. J Rheumatol 2020;47(6):839-46.
  39. Ritchlin C, Scher JU. Strategies to Improve Outcomes in Psoriatic Arthritis. Curr Rheumatol Rep 2019;21(12):72.
  40. Dong Y, Peng CY. Principled missing data methods for researchers. Springerplus 2013;2(1):222.